EASL – AASLD JOINT MEETING
Definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis

London, United Kingdom
30 September, 1 October 2017

Organising Committee:
Philippe Mathurin, France
Vijay Shah, United States
Gyongyi Szabo, United States
Mark Thursz, United Kingdom

Saturday 30 September 2017

07:30 – 08:50 Registration

08:50 – 09:00 Welcome and opening remarks
Gyongyi Szabo and Philippe Mathurin

Session 1: Epidemiology and progression factors of ALD
Chair: Nick Sheron, United Kingdom

09:00 – 09:20 Burden and epidemiology of alcohol-related liver diseases in Europe and North America
David Leon, United Kingdom

09:20 – 09:40 Put us out of business: Role of health policy in controlling alcohol consumption
Sir Ian Gilmore, United Kingdom

09:40 – 10:00 Genetics of ALD: What do we learn from the risk loci about the disease?
Jochen Hampe, Germany

10:00 – 10:15 Discussion

10:15 – 10:35 Coffee break and ePoster session 1

Session 2: Translational science in ALD
Chair: Tim Morgan, United States

10:35 – 10:55 Alcohol metabolism and cellular consequences
Laura Nagy, United States

10:55 – 11:15 From microbiome to intestinal inflammation in ALD
Bernd Schnabl, United States

11:15 – 11:50 Discussion
11:50 – 13:15  
**Lunch and ePoster session 2+3**

13:15 – 13:35  
Inflammation as a driver of ALD  
Gyongyi Szabo, United States

13:35 – 13:55  
Alcohol related fibrogenesis  
Christian Trautwein, Germany

13:55 – 14:15  
Impaired pathways of liver regeneration in chronic liver disease: future therapeutic target for severe ALD?  
Anna Mae Diehl, United States

14:15 – 14:35  
Animal models of ALD and alcoholic hepatitis: I favour the NIAAA model for targeting the key therapeutic pathways  
Bin Gao, United States

14:35 – 14:55  
I favour the intragastric fat/alcohol model or targeting the key therapeutic pathways  
Hidekazu Tsukamoto, United States

14:55 – 15:10  
Discussion

15:10 – 15:30  
**Coffee break and ePoster session 4**

### Session 3: Clinical challenges in the management of patients with ALD  
Chair: Carolin Lackner, Austria

15:30 – 16:00  
Alcohol use disorder: diagnosis and management  
Giovanni Addolorato, Italy

16:00 – 16:20  
Assessing co-factors in ALD  
Arun Sanyal, United States

16:20 – 16:35  
Liver histology and AH/ALD-what is its role?  
Dina Tiniakos, United Kingdom

16:35 – 16:55  
Liquid biopsy and biomarkers as a diagnostic measure and surrogate end-points  
Vijay Shah, United States

16:55 – 17:15  
Non-invasive assessment including imaging in early versus advanced ALD  
Laurent Castera, France

17:15 – 17:30  
Discussion

17:30 – 18:00  
**State-of-the-Art Lecture:** Molecular pathways in hepatocellular carcinoma  
Michael Karin, United States

18:00 – 19:00  
**Welcome reception and ePoster session 5+6**

20:00  
Faculty dinner
Sunday 1 October 2017

Session 4: Management and treatment of alcoholic hepatitis (AH)
Chair: John O’Grady, London, United Kingdom

08:00 – 08:20  Acute AH: Defining disease severity (severe vs. moderate AH) and prognostic models of lethality and survival
Patrick Kamath, United States

08:20 – 08:40  SIRS and management of infection in AH
Ramon Bataller, United States

08:40 – 08:55  Early liver transplantation in AH – Pro and Con debate:
I do not favour broader use of early liver transplantation for AH
Michael Lucey, United States

8:55 - 9:10   I favour broader use of early liver transplantation in AH
Philippe Mathurin, France

09:10 – 09:30  Post-transplant complications/what is specific for ALD
Patrizia Burra, Italy

09:30 – 09:50  Alcohol relapse after transplantation: does-it matter?
Georges-Philippe Pageaux, France

09:50 – 10:05  Discussion

10:05 – 10:25  Coffee break and ePoster session 7

Session 5: Clinical trial design and end-points: perspectives of agencies

Chair: Helmut Seitz, Germany

10:25 – 10:45  Cost and mortality attributed to ALD
Rehm Jürgen, Canada

10:45 – 11:05  Regulatory process to validate biomarkers and end-points for drug approval: specific requirements for AH
Christopher Leptak, United States

11:05 – 11:25  EMA process to validate end-points for drug approval: specific requirements for AH
EMA

11:25 – 11:40  Discussions

11:40 – 13:00  Lunch and ePoster Session 8
Session 6: Future development of drugs in alcoholic hepatitis: Perspectives of the investigators

**Chair: Laurent Spahr, Switzerland**

13:00 – 13:20  Patient characteristics and end-points in clinical trials for early ALD
*Helena Cortez Pinto, Portugal*

13:20 – 13:40  Current treatments in alcoholic hepatitis (lessons learned) and ongoing clinical trials
*Mark Thursz, United Kingdom*

13:40 – 14:00  Clinical trial design: What is the optimal plan of development from phase I to Phase III?
*Alexandre Louvet, France*

14:00 – 14:20  How can large epidemiologic studies, registries and bio-banks may help in the setting of AH and ALD
*Alexander Krag, Denmark.*

14:20 – 14:40  Lessons learned from NASH CRN and DILI network on clinical networks, sample and data collection
*Naga Chalasani, United States*

14:40 – 15:00  Which therapeutic targets will be the most attractive in the future?
*Craig McClain, United States*

15:00 – 15:30  Break and poster session

Session 7: Future development of drugs in alcoholic hepatitis: Industry perspectives

**Chair: Mack Mitchell, USA**

15:30-16:45  3-4 pharma leaders to give a brief, 5-8 min overview of their plans/perspectives/challenges on clinical trials in ALD/AH
Give each 15 min (presentation+ discussion)

16:45  Discussions & Closing Remarks
*Vijay Shah and Mark Thursz*